<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05629390</url>
  </required_header>
  <id_info>
    <org_study_id>LB4001-301</org_study_id>
    <nct_id>NCT05629390</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study</brief_title>
  <official_title>Randomized Controlled, Multicenter, Double-Masked, Parallel Phase III Trial to Evaluate the Efficacy and Safety of Lotilaner Ophthalmic Solution for the Treatment of Demodex Blepharitis in China With an Open-Label Pharmacokinetics Sub-Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LianBio LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LianBio LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase III main study is a randomized, controlled, multicenter, double blind, trial to&#xD;
      evaluate the efficacy and safety of TP-03 (lotilaner ophthalmic solution, 0.25%), for the&#xD;
      treatment of Demodex blepharitis in Chinese patients. The PK sub-study is a single-arm,&#xD;
      open-label trial to evaluate systemic TP-03 in whole blood following topical ocular&#xD;
      administration&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main study is designed to demonstrate the superiority of TP-03 compared to vehicle for&#xD;
      the treatment of Demodex blepharitis in Chinese patients. The vehicle of TP-03 was selected&#xD;
      as the control since there are no approved pharmaceutical treatments for Demodex blepharitis.&#xD;
      The vehicle as the control will provide evidence that the active ingredient is responsible&#xD;
      for the response, not the vehicle alone.&#xD;
&#xD;
      A pharmacokinetics (PK) sub-study is included in the overall study design to evaluate&#xD;
      systemic PK parameters of TP-03 in Chinese participants with Demodex blepharitis. The PK&#xD;
      sub-study sites are separate from those of the Phase III study as described above.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2022</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of participants cured based on their collarette score of 0 for the upper eyelid of the analysis eye.</measure>
    <time_frame>43 days</time_frame>
    <description>To demonstrate the efficacy of 0.25% Lotilaner Ophthalmic Solution to eliminate collarettes and eradicate mite in Demodex blepharitis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The assessment of treatment-related adverse effects</measure>
    <time_frame>43 days</time_frame>
    <description>To demonstrate the efficacy of 0.25% Lotilaner Ophthalmic Solution to eliminate collarettes and eradicate mite in Demodex blepharitis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-related adverse effects</measure>
    <time_frame>43 days</time_frame>
    <description>To demonstrate the safety of 0.25% TP-03 in Demodex blepharitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants cured based on a composite of collarette score of 0 and erythema score of 0 for the upper eyelid of the analysis eye</measure>
    <time_frame>43 days</time_frame>
    <description>To demonstrate the efficacy of TP-03 to eliminate collarettes and erythema from the eyelid margin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood drug concentration of Lotilaner at Day 1 and Day 43</measure>
    <time_frame>43 days</time_frame>
    <description>To evaluate the blood drug concentration of Lotilaner following topical ocular administration of TP-03administration of 0.25% TP-03</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>Lotilaner Ophthalmic Solution (TP-03)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lotilaner Ophthalmic Solution (TP-03)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lotilaner</intervention_name>
    <description>Lotilaner Ophthalmic Solution</description>
    <arm_group_label>Lotilaner Ophthalmic Solution (TP-03)</arm_group_label>
    <other_name>TP-03</other_name>
    <other_name>S-Misoxam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Control</intervention_name>
    <description>Vehicle of TP-03 ophthalmic solution</description>
    <arm_group_label>Vehicle Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, aged â‰¥ 18 years of age.&#xD;
&#xD;
          2. Be willing to sign the informed consent and deemed capable of complying with the&#xD;
             requirements of the study protocol.&#xD;
&#xD;
          3. Has blepharitis&#xD;
&#xD;
          4. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have used lid hygiene products (e.g., lid scrubs) within 14 days of Screening or&#xD;
             unwilling to forego the use of lid hygiene products during the study.&#xD;
&#xD;
          2. Have initiated treatment with an ocular topical prostaglandin analogue within 30 days&#xD;
             of Screening or have any plans to change or discontinue treatment during the study&#xD;
&#xD;
          3. Pregnancy or lactation.&#xD;
&#xD;
          4. Any intraocular surgery (including ocular surface surgery, cataract surgery and&#xD;
             intravitreal injection) or periocular surgery within 60 days prior to randomization,&#xD;
             or any planned ocular surgical procedure during the study period&#xD;
&#xD;
          5. Have any unstable or uncontrolled, cardiac, pulmonary, renal, oncological,&#xD;
             neurological, metabolic or other systemic condition that, in the opinion of the&#xD;
             investigator, would possibly require the participant to seek emergent medical&#xD;
             treatment during the course of this study. This includes, but is not limited to,&#xD;
             unstable or uncontrolled cardiac arrhythmias, hypertension, coagulopathies, renal&#xD;
             failure or advanced diabetes mellitus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zuguo Liu, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiamen Eye Center of Xiamen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qi Wang</last_name>
    <phone>+862123081188</phone>
    <email>qi.wang@lianbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ying Jie</last_name>
      <email>dr_jieying@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jing Hong</last_name>
      <email>hongjing1964@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Aier Eye Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi Ren</last_name>
      <email>renxabu@icloud.com</email>
    </contact>
    <contact_backup>
      <last_name>Yi Wang</last_name>
      <email>wangyieye@aliyun.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Xiamen Eye Center of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zuguo Liu</last_name>
      <phone>+8618959289999</phone>
      <email>zuguoliu@xmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou Aier Eye Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donghao Li</last_name>
      <email>ldh71@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linyi Liang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hainan Eye Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingwu Zhong</last_name>
      <email>xingzh88@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150007</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hong Zhang</last_name>
      <email>13804505456@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial Eye Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Zhu</last_name>
      <email>hnyks135@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mingchang Zhang</last_name>
      <email>mingchangzhang@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuan Xiao</last_name>
      <phone>15327218573</phone>
      <email>xiaoxuan1111@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410007</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhuo Li</last_name>
      <email>xy2gcpli@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hua Wang</last_name>
      <email>wanghua1026@csu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of University of South China</name>
      <address>
        <city>Hengyang</city>
        <state>Hunan</state>
        <zip>421001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gang Tan</last_name>
      <email>tangang99@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuxi Second People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Song Sun</last_name>
      <email>charmingpisces@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eye&amp; Ent Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiaxu Hong</last_name>
      <email>jiaxu_hong@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200940</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Zhao</last_name>
      <email>20887787@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial Eye Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaofen Zheng</last_name>
      <email>Pizxf163@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Eye Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300392</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shaozhen Zhao</last_name>
      <email>zhaosz1997@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuming Jin</last_name>
      <email>lzyjxm@zju.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eye Hospital, Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Chen</last_name>
      <email>chenweiwmc@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>November 17, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>February 13, 2023</last_update_submitted>
  <last_update_submitted_qc>February 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blepharitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

